Healthcare Services

NGS Oncology Market Forecast 2026–2035 Highlighting Market Data Patterns and Industry Insights

April 3, 2026April 3, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Expected Market Size Of The NGS Oncology Market From 2026 To 2030?

The ngs oncology market has experienced substantial expansion recently. Its size is projected to increase from $19.33 billion in 2025 to $21.54 billion in 2026, at a compound annual growth rate (CAGR) of 11.4%. The observed growth in the historic period can be attributed to factors such as declining sequencing costs, rising global cancer prevalence, increased oncology research funding, early adoption of targeted therapies, and the growth of genomic research initiatives.

The ngs oncology market is projected to experience substantial expansion over the upcoming years. Its valuation is anticipated to reach $32.87 billion by 2030, driven by a compound annual growth rate (CAGR) of 11.2%. This growth throughout the forecast period stems from factors such as the proliferation of precision oncology initiatives, the increasing need for individualized cancer therapies, a rise in approvals for ngs-based diagnostic tools, progress in bioinformatics analytics, and the incorporation of ngs into established clinical protocols. Key developments expected during this timeframe encompass the broadening scope of comprehensive tumor profiling, the growing acceptance of liquid biopsy NGS, enhanced clinical usefulness of multi-gene panels, the incorporation of NGS into standard oncology diagnostic practices, and an escalating requirement for more expeditious sequencing workflows.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24337&type=smp

What Major Drivers Are Influencing Demand In The NGS Oncology Market?

The increasing occurrence of cancer is projected to stimulate expansion in the NGS oncology market in the coming years. Cancer is a condition characterized by the uncontrolled proliferation of abnormal cells that can infiltrate other bodily regions, disrupting regular physiological operations. This rise in cancer cases is largely attributed to an aging global population, overall population expansion, and heightened exposure to risk factors like tobacco consumption, alcohol intake, excess weight, and atmospheric pollution. NGS oncology contributes significantly to public health and patient well-being by facilitating prompt detection, accurate diagnosis, and tailored treatment plans through comprehensive genetic analysis of tumors. For example, in January 2024, data released by the American Cancer Society, a US-based non-profit organization, indicated that the United States is anticipated to record 2,001,140 new cancer cases and 611,720 cancer deaths in 2024, a notable increase from 1,958,310 cases and 609,820 deaths in 2023. Consequently, the growing prevalence of cancer is propelling the development of the NGS oncology market.

Which Segments Are Included In The Analysis Of The NGS Oncology Market?

The ngs oncology market covered in this report is segmented –

1) By Sequencing Technology: Targeted Sequencing, Genomics, Transcriptomics, Epigenomics

2) By Offering: Platform, Kits, Services

3) By Workflow: Pre-Sequencing, Sequencing, Data Analysis

4) By Application: Genetic Screening, Hereditary Genetic Testing, Hematological Malignancies, Solid Tumors, Other Applications

5) By End User: Hospitals And Clinics, Clinical Research Organizations (CROs), Academic And Research Institutes, Pharmaceutical And Biotechnology Companies, Other End Users

Subsegments:

1) By Targeted Sequencing: Whole Exome Sequencing (WES), Amplicon-Based Sequencing, Hybridization-Based Sequencing

2) By Genomics: Whole Genome Sequencing (WGS), Structural Variant Detection, Copy Number Variation (CNV) Analysis

3) By Transcriptomics: RNA Sequencing, Single-Cell Transcriptomics, Non-Coding RNA Analysis

4) By Epigenomics: DNA Methylation Sequencing, Chromatin Immunoprecipitation Sequencing, Histone Modification Analysis

How Are Trends Transforming The NGS Oncology Market Landscape?

Leading companies in the NGS oncology market are dedicated to developing innovative solutions, such as liquid biopsy research assays, to facilitate non-invasive, real-time cancer detection and monitoring by analyzing circulating tumor DNA. These diagnostic tests examine biological fluids, including blood, to identify genetic mutations or other molecular markers associated with cancer. For instance, in August 2024, Illumina Inc., a US-based biotechnology company specializing in next-generation sequencing (NGS) technology, broadened its oncology portfolio for NovaSeq X Series users. The company now provides the newly validated high-throughput TruSight Oncology 500 (TSO 500 HT) and the updated TruSight Oncology 500 ctDNA v2 (TSO 500 ctDNA v2) liquid biopsy research assay. These enhanced assays empower laboratories to expand oncology research capabilities for both tissue and liquid biopsy samples, offering improved sequencing efficiency, shorter run times, and the new ability to process larger sample volumes on the NovaSeq X Series.

Which Key Industry Participants Are Active In The NGS Oncology Market?

Major companies operating in the ngs oncology market are Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Agilent Technologies Inc., Eurofins Scientific SE, Illumina Inc., Qiagen N.V., Tecan Trading AG, Myriad Genetics, Takara Bio Inc., Beijing Genomics Institute (BGI), Caris Life Sciences, Foundation Medicine, Paradigm Diagnostics, Pacific Bioscience, Horizon Discovery Group plc , Creative-Biolabs, Xcelris Labs Ltd., Partek Inc., 4baseCare, SciGenom Labs Pvt. Ltd.

Read the full ngs oncology market report here:

https://www.thebusinessresearchcompany.com/report/ngs-oncology-global-market-report

Which Region Shows The Strongest Potential For Future Growth In The NGS Oncology Market?

North America was the largest region in the NGS oncology market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ngs oncology market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored NGS Oncology Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24337&type=smp

Browse Through More Reports Similar to the Global NGS Oncology Market 2026, By The Business Research Company

Ngs Based Rna Sequencing Global Market Report

https://www.thebusinessresearchcompany.com/report/ngs-based-rna-sequencing-global-market-report

Prenatal Dna Sequencing Global Market Report

https://www.thebusinessresearchcompany.com/report/prenatal-dna-sequencing-global-market-report

Next Generation Firewall Global Market Report

https://www.thebusinessresearchcompany.com/report/next-generation-firewall-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795